{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T17:12:01Z","timestamp":1776273121010,"version":"3.50.1"},"reference-count":13,"publisher":"American Association for Cancer Research (AACR)","issue":"10","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The bone microenvironment plays a critical role in supporting the growth and survival of multiple myeloma as well as in the development of osteolytic bone disease. Signaling through p38\u03b1 mitogen-activated protein kinase (MAPK) mediates synthesis of multiple myeloma cell growth factors, and its inhibition reduces proliferation in vitro. However, it is unclear whether targeting p38\u03b1 MAPK prevents multiple myeloma growth and the development of bone disease in vivo. In this study, we determined whether SCIO-469, a selective p38\u03b1 MAPK inhibitor, inhibits multiple myeloma growth and prevents bone disease in the 5T2MM and 5T33MM models. SCIO-469 decreased constitutive p38\u03b1 MAPK phosphorylation of both 5T2MM and 5T33MM cells in vitro. This was associated with decreased DNA synthesis and an induction of apoptosis when the cells were cultured with bone marrow stromal cells. Treatment of C57Bl\/KaLwRij mice bearing 5T33MM cells with SCIO-469 inhibited p38\u03b1 MAPK phosphorylation and was associated with a significant decrease in serum paraprotein, an almost complete reduction in tumor cells in the bone marrow, a decrease in angiogenesis, and a significant increase in disease-free survival. Injection of 5T2MM murine myeloma cells into C57Bl\/KaLwRij mice resulted in myeloma bone disease characterized by increased osteoclast occupation of the bone surface, reduced cancellous bone, and the development of osteolytic bone lesions. Treatment of 5T2MM-injected mice with SCIO-469 reduced this development of bone disease. Together, these data show that targeting p38\u03b1 MAPK with SCIO-469 decreases myeloma burden in vivo, in addition to preventing the development of myeloma bone disease. [Cancer Res 2007;67(10):4572\u20137]<\/jats:p>","DOI":"10.1158\/0008-5472.can-06-4361","type":"journal-article","created":{"date-parts":[[2007,5,11]],"date-time":"2007-05-11T01:44:56Z","timestamp":1178847896000},"page":"4572-4577","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Inhibition of p38\u03b1 Mitogen-Activated Protein Kinase Prevents the Development of Osteolytic Bone Disease, Reduces Tumor Burden, and Increases Survival in Murine Models of Multiple Myeloma"],"prefix":"10.1158","volume":"67","author":[{"given":"Karin","family":"Vanderkerken","sequence":"first","affiliation":[{"name":"1Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya","family":"Medicherla","sequence":"additional","affiliation":[{"name":"2Scios, Inc., Fremont, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Les","family":"Coulton","sequence":"additional","affiliation":[{"name":"3Academic Unit of Bone Biology, University of Sheffield School of Medicine and Biomedical Science, Sheffield, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hendrik","family":"De Raeve","sequence":"additional","affiliation":[{"name":"4Department of Pathology, University Hospital Antwerp, Antwerp, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Willems","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Lawson","sequence":"additional","affiliation":[{"name":"3Academic Unit of Bone Biology, University of Sheffield School of Medicine and Biomedical Science, Sheffield, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Van Camp","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew A.","family":"Protter","sequence":"additional","affiliation":[{"name":"2Scios, Inc., Fremont, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S.","family":"Higgins","sequence":"additional","affiliation":[{"name":"2Scios, Inc., Fremont, California;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline","family":"Menu","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Immunology, Vrije Universiteit Brussel (VUB), Brussels, Belgium;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter I.","family":"Croucher","sequence":"additional","affiliation":[{"name":"3Academic Unit of Bone Biology, University of Sheffield School of Medicine and Biomedical Science, Sheffield, United Kingdom; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2007,5,17]]},"reference":[{"key":"2022061623210749600_B1","doi-asserted-by":"crossref","unstructured":"Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood\u20082003; 101: 703\u20135.","DOI":"10.1182\/blood-2002-06-1874"},{"key":"2022061623210749600_B2","doi-asserted-by":"crossref","unstructured":"Nguyen AN, Stebbins EG, Henson M, et al, Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res\u20082006; 312: 1909\u201323.","DOI":"10.1016\/j.yexcr.2006.02.026"},{"key":"2022061623210749600_B3","doi-asserted-by":"crossref","unstructured":"Hideshima T, Podar K, Chauhan D, et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene\u20082004; 23: 8766\u201376.","DOI":"10.1038\/sj.onc.1208118"},{"key":"2022061623210749600_B4","doi-asserted-by":"crossref","unstructured":"Navas TA, Nguyen AN, Hideshima T, et al. Inhibition of p38\u03b1 MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia\u20082006; 20: 1017\u201327.","DOI":"10.1038\/sj.leu.2404200"},{"key":"2022061623210749600_B5","doi-asserted-by":"crossref","unstructured":"Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood\u20082006; 107: 2432\u20139.","DOI":"10.1182\/blood-2005-06-2486"},{"key":"2022061623210749600_B6","doi-asserted-by":"crossref","unstructured":"Wang S, Hong S, Yang J, et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patient's monocyte-derived dendritic cells by inhibiting p38 or activating MEK\/ERK MAPK and neutralizing interleukin-6 in the progenitor cells. Blood\u20082006; 108: 4071\u20137.","DOI":"10.1182\/blood-2006-04-016980"},{"key":"2022061623210749600_B7","doi-asserted-by":"crossref","unstructured":"Radl J, De Glopper ED, Schuit HR, Zurcher C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL\/KaLwRij mice. J Immunol\u20081979; 122: 609\u201313.","DOI":"10.4049\/jimmunol.122.2.609"},{"key":"2022061623210749600_B8","doi-asserted-by":"crossref","unstructured":"Vanderkerken K, Asosingh K, Croucher P, Van Camp B. Multiple myeloma biology: lessons from the 5TMM models [review]. Immunol Rev\u20082003; 194: 196\u2013206.","DOI":"10.1034\/j.1600-065X.2003.00035.x"},{"key":"2022061623210749600_B9","doi-asserted-by":"crossref","unstructured":"Vanderkerken K, Asosingh K, Willems A, et al. The 5T2MM murine model of multiple myeloma: maintenance and analysis. Methods Mol Med\u20082005; 113: 191\u2013205.","DOI":"10.1385\/1-59259-916-8:191"},{"key":"2022061623210749600_B10","doi-asserted-by":"crossref","unstructured":"Vanderkerken K, Goes E, De Raeve H, Radl J, Van Camp B. Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography. Br J Cancer\u20081996; 73: 1463\u20135.","DOI":"10.1038\/bjc.1996.277"},{"key":"2022061623210749600_B11","doi-asserted-by":"crossref","unstructured":"Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res\u20082003; 18: 482\u201392.","DOI":"10.1359\/jbmr.2003.18.3.482"},{"key":"2022061623210749600_B12","doi-asserted-by":"crossref","unstructured":"Van Valckenborgh E, De Raeve H, Devy L, et al. Murine 5T multiple myeloma cells induce angiogenesis in vitro and in vivo. Br J Cancer\u20082002; 86: 796\u2013802.","DOI":"10.1038\/sj.bjc.6600137"},{"key":"2022061623210749600_B13","doi-asserted-by":"crossref","unstructured":"Menu E, Jernberg-Wiklund H, Stromberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood\u20082006; 107: 655\u201360.","DOI":"10.1182\/blood-2005-01-0293"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/10\/4572\/2569581\/4572.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/10\/4572\/2569581\/4572.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T19:40:38Z","timestamp":1683834038000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/10\/4572\/533130\/Inhibition-of-p38-Mitogen-Activated-Protein-Kinase"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5,15]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2007,5,17]]},"published-print":{"date-parts":[[2007,5,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-06-4361","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5,15]]}}}